Sanz M J, Weg V B, Bolanowski M A, Nourshargh S
Department of Applied Pharmacology, National Heart and Lung Institute, London, United Kingdom.
J Immunol. 1995 Feb 1;154(3):1364-73.
The aim of the present study was to investigate directly and characterize the ability of IL-1 beta in inducing eosinophil accumulation in vivo. For this purpose, we studied the recruitment of 111In-labeled eosinophils in rat skin in response to intradermally injected rat rIL-1 beta. Rat rIL-1 induced a dose-dependent accumulation of 111In-labeled eosinophils, with the maximal response being detected at 5 x 10(-13) mol/site. This response was slow in onset, progressively increasing over the 4-h period investigated. Rat rIL-1 also induced a small level of edema, as measured by the local accumulation of i.v. 125I-labeled albumin, which developed with a time course similar to that of 111In-labeled eosinophil accumulation. Co-administration of the cytokine with the IL-1R antagonist, IL-1ra, or actinomycin D, significantly inhibited the 111In-labeled eosinophil accumulation, and reduced the edema formation, induced by rat rIL-1. In addition, the 111In-labeled eosinophil accumulation was significantly suppressed in animals treated with the PAF antagonist UK-74,505 or an anti-human IL-8 mAb DM/C7. These observations demonstrate for the first time that IL-1 beta is a potent inducer of eosinophil accumulation in vivo. Moreover, the results reveal that this activity of IL-1 beta is receptor mediated and dependent on the induction of proteins that may be involved in the local generation of secondary inflammatory mediators including PAF and an IL-8-like molecule. These findings are consistent with the view that endogenously generated IL-1 may play an important role in the recruitment of eosinophils at sites of allergic inflammation.
本研究的目的是直接研究并表征白细胞介素-1β(IL-1β)在体内诱导嗜酸性粒细胞积聚的能力。为此,我们研究了大鼠皮肤中响应皮内注射大鼠重组IL-1β(rat rIL-1β)的铟-111(111In)标记嗜酸性粒细胞的募集情况。大鼠rIL-1诱导了111In标记嗜酸性粒细胞的剂量依赖性积聚,在5×10⁻¹³mol/部位检测到最大反应。这种反应起效缓慢,在所研究的4小时内逐渐增加。大鼠rIL-1还诱导了少量水肿,通过静脉注射125I标记白蛋白的局部积聚来测量,其发展的时间进程与111In标记嗜酸性粒细胞积聚相似。细胞因子与IL-1受体拮抗剂IL-1ra或放线菌素D共同给药,显著抑制了111In标记嗜酸性粒细胞的积聚,并减少了大鼠rIL-1诱导的水肿形成。此外,在使用血小板活化因子(PAF)拮抗剂UK-74,505或抗人IL-8单克隆抗体DM/C7处理的动物中,111In标记嗜酸性粒细胞的积聚被显著抑制。这些观察结果首次证明IL-1β是体内嗜酸性粒细胞积聚的有效诱导剂。此外,结果表明IL-1β的这种活性是受体介导的,并且依赖于可能参与包括PAF和一种IL-8样分子在内的继发性炎症介质局部产生的蛋白质的诱导。这些发现与内源性产生的IL-1可能在过敏性炎症部位嗜酸性粒细胞募集中起重要作用的观点一致。